Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant Infected With HIV-1.
Participant for whom raltegravir therapy has been decided and started less than 30 days prior to inclusion in the study.
Participant who has received oral and written information about the study and who has agreed to the computer processing of his/her personal data.
You may not be if
Participant taking part in a clinical trial to assess raltegravir.
Participant in whom raltegravir treatment was started more than 30 days ago.
Clareo Health | Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
